Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Which Cocoa ETF Is Right For You? NIB vs. CHOC

Investors have long been intrigued with cocoa, as this sweet commodity has surely made a name for itself in the financial universe. Although its uses are limited, the market demand for this resource is quite massive. Cocoa is primarily used in the production of chocolate, but can also be used to make cocoa butter, which is used in a number of pharmaceutical drugs. Additionally, cocoa makes an appearance in cosmetics, including various kinds of makeup, lotions, and even soap.

By far, the largest producer of the soft commodity is the Ivory Coast, followed by big name producers in Ghana, Nigeria, and Cameroon. As a trading instrument, cocoa is a rather appealing short-term play since supply shocks can often send prices skyward. And thanks to the development of the exchange-traded fund industry, investors now have several ways to gain access to this popular sweet commodity. Below, we outline the two most popular cocoa ETFs and which one will fit your investment objectives [for more cocoa news and analysis subscribe to our free newsletter].

iPath DJ-UBS Cocoa Subindex Total Return SM Index (NYSEARCA:NIB)

Quick Stats (10/12/2012)

Total Assets: $31.1 million
Average Daily Volume: 43,000
Expense Ratio: 0.75%
In Depth: NIB Analyst Report and ETFdb Realtime Rating

Barclays iPath’s NIB is by far the most popular cocoa ETN available on the market, offering investors exposure to the sweet commodity by investing in a single futures contract on cocoa. Since its debut in 2008, NIB has grown in popularity as investors look at the fund as an effective speculative tool to make a play on the cocoa market. The cleverly-named fund has accumulated over $31 million in total assets, and its shares currently exchange hands nearly 43,000 times a day on average. It is also important to note that NIB is structured as an exchange-traded note, meaning investors will be exposed to the potential credit risk of the issuing  institution.

NIB is Right for You if: You are an active trader seeking to either speculate on cocoa’s movements or quickly execute positions in the commodity.

iPath Pure Beta Cocoa (NYSEARCA:CHOC)

Quick Stats (10/12/2012)

Total Assets: $7.2 million
Average Daily Volume: 9,200
Expense Ratio: 0.75%
In Depth: CHOC Analyst Report and ETFdb Realtime Rating

CHOC is the only other exchange-traded product available on the market, offering investors exposure to cocoa prices through the futures market, but with a slight twist. Unlike NIB which rolls its holdings on a monthly basis, CHOC does not roll exposure on a predetermined schedule; the roll timing is based on a proprietary “Pure Beta” methodology designed to reduce the impact of contango or backwardation on returns. This is perhaps the fund’s most alluring feature, considering how both of these futures trading nuances can make a devastating impact on bottom line returns. Despite its contango-fighting feature, the fund is by no means at the same level of popularity as its competitor, NIB: CHOC has only $7.2 million in total assets compared to NIB’s $31 million portfolio and its average daily volume comes in at arelatively low 9,200 shares.

CHOC is Right for You if: You are an investor looking to achieve cocoa futures exposure, but want a methodology that helps avoid the adverse affects of contango.

This article was originally written by Daniela Pylypczak, and posted on CommodityHQ.

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!